Articles tagged with Vitiligo
Researchers at the University of São Paulo have developed nanoparticles that deliver therapeutic RNA molecules directly to skin cells, silencing genes responsible for chronic inflammation. This precision nanomedicine approach holds promise for treating complex diseases like psoriasis and vitiligo.
A natural compound derived from gut-friendly bacteria significantly slows vitiligo progression and may restore pigmentation in mice. The findings could offer hope to millions affected by the autoimmune disease, which causes visible patches of skin discoloration and carries profound emotional and physical consequences.
Researchers from Osaka Metropolitan University have discovered that disruptions in the basement membrane zone between the epidermis and dermis could make it harder for pigment-producing cells to adhere. An enzyme called matrix metalloproteinase 2 (MMP2) may be overexpressed, leading to disturbance of the basement membrane.
A new Northwestern Medicine study reveals that 73% of children with skin diseases face stigma and bullying, leading to impaired relationships and mental health issues such as depression and anxiety. The study suggests that clinicians should aggressively treat skin disorders in children and consider referral to evaluation and counseling.
A study published in the Journal of Investigative Dermatology found that patients with vitiligo incur significantly higher healthcare costs than those without the condition. The research analyzed direct and indirect healthcare costs associated with vitiligo, revealing an unmet need for cost-effective treatments.
Researchers discovered distinct mechanisms controlling different types of immune cells and found a way to selectively eliminate 'problematic' cells driving autoimmune disorders. This breakthrough offers precise targets for potential treatment strategies, potentially revolutionizing the way we treat skin conditions.
Patients with vitiligo show a 25% decreased risk of mortality compared to controls, suggesting an autoimmune protective effect. The study found lower mortality rates for patients with vitiligo due to cancer and other causes, offering new avenues for research into mechanisms underlying this protective effect.
Researchers identified distinct subpopulations of keratinocytes and changes in cellular compositions that drive disease persistence. The findings raise the possibility of targeting keratinocyte metabolism in Vitiligo treatment.
New studies by CU researchers reveal that both genetic and environmental factors play significant roles in the onset of vitiligo. The findings suggest that unidentified factors contribute to the disease's complex etiology, complicating personalized medicine approaches.
A nationwide clinical trial found that topical application of ruxolitinib was effective in repigmenting the skin of over 50% of participants with facial vitiligo. The treatment has an excellent safety profile and may lead to better results when combined with phototherapy and sunlight exposure.
Researchers found targeting resident memory T cells restores pigmentation in mouse model of vitiligo, offering potential new treatment. Current treatments can restore color but depigmentation recurs in up to 40% of cases.
A study published in Journal of the American Academy of Dermatology shows that MKTP surgery can restore skin pigmentation in vitiligo patients for up to five years. The procedure, which involves transplanting melanocyte cells, demonstrates long-term benefits with high repigmentation rates.
Researchers identified 23 locations on the human genome linked to vitiligo susceptibility. The study provides a framework for understanding the genetic architecture and biological mechanisms of vitiligo, highlighting relationships with other autoimmune diseases.
A Yale University study found that an arthritis medication restored skin color in a vitiligo patient after just two months of treatment. The patient experienced partial repigmentation on her face, arms, and hands, with nearly all white spots gone after five months.
A new treatment regimen has been found to be safe and effective in restoring skin pigmentation in vitiligo patients. The study, led by Henry Ford Hospital, showed that a combination of afamelanotide and phototherapy using narrowband ultraviolet-B rays resulted in faster repigmentation compared to UVB treatment alone.
Patients with vitiligo experienced faster and better repigmentation after combining afamelanotide with narrowband UV-B phototherapy. The study found significant improvements in facial and upper extremity repigmentation rates compared to phototherapy alone.
A study of 282 patients with chronic graft-vs-host disease found a link between female donors and the development of vitiligo and alopecia areata. The study identified risk factors, including sex mismatch and certain antibodies, which may lead to better understanding of autoimmune manifestations in this condition.
Researchers developed a new compound called PC-KUS that reduces hydrogen peroxide accumulation in the hair follicle, reversing gray hair. The treatment also works on vitiligo, a skin condition causing loss of pigment, with successful repigmentation outcomes observed.
Researchers developed a genetically modified protein that reverses vitiligo in mice and shows similar effects on human skin tissue samples. The modified protein, called mutant HSP70i, supplants normal HSP70i, thereby reversing the autoimmune response that causes vitiligo.
Researchers found that skin transplant surgery is safe and effective in treating vitiligo, with treated areas regaining an average of 43-68% of their natural skin color. The procedure involves transferring melanocyte cells from healthy skin to damaged areas.
A study published in Nature Genetics found a correlation between eye color and the risk of developing certain serious skin conditions. People with blue eyes were less likely to have vitiligo, while those with brown eyes may be at lower risk for melanoma.
Researchers have discovered variations in 10 genes associated with immune response in people with vitiligo, pointing to multiple cellular pathways contributing to the disease. The findings offer potential starting points for developing therapies tailored to individual genetic susceptibilities.
Researchers at Henry Ford Hospital conducted a study showing that skin transplant surgery is safe and effective in treating vitiligo. The treated area regained an average of 52% of its natural skin color, with some patients experiencing up to 74% regrowth.
Researchers discovered a higher frequency of vitiligo in a Romanian community compared to surrounding populations, suggesting a genetic component. However, the disease's onset required environmental triggers, indicating that genetics alone may not be enough to explain its development.
Researchers discovered a key gene, NALP1, associated with vitiligo and other autoimmune diseases. The gene controls the innate immune system and may help trigger these conditions.
Researchers found that pigment cell grafts resulted in significant repigmentation in patients with stable vitiligo, with 55-77% of treated areas regaining pigmentation over 3-12 months. Long-term efficacy was also demonstrated in another study, showing sustained repigmentation in up to 95% of patients.
Researchers found that combining 308-nm excimer laser therapy with topical tacrolimus ointment resulted in 100% repigmentation in group A lesions and 85% in group B. The treatment was well tolerated, with an average of 10-12 sessions needed to see improvement.